July 3rd 2020, 1:00pm
Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.
July 2nd 2020, 7:00pm
In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.
July 2nd 2020, 12:36am
Solange Peters, MD, PhD, discusses ongoing research with fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in patients with HER2-mutated non–small cell lung cancer.
June 29th 2020, 7:52pm
The Japanese Ministry of Health, Labor, and Welfare has approved capmatinib for patients with MET exon 14 skipping mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer.
June 29th 2020, 6:37pm
Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.
June 25th 2020, 4:02pm
A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.
June 24th 2020, 1:00am
The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.
June 24th 2020, 12:34am
Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.
June 23rd 2020, 11:37pm
Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.
June 23rd 2020, 8:21pm
Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.
